Scarica l'app Stockscreener
453.54
1.37%
6.11
Pre-mercato:
454.60
1.06
+0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
How high can Alnylam Pharmaceuticals Inc. stock goWeekly Profit Report & Consistent Return Strategy Ideas - Newser
Multi asset correlation models including Alnylam Pharmaceuticals Inc.GDP Growth & AI Forecast Swing Trade Picks - Newser
Using RSI to spot recovery in Alnylam Pharmaceuticals Inc.July 2025 Reactions & Fast Exit/Entry Strategy Plans - Newser
How to use a screener to detect Alnylam Pharmaceuticals Inc. breakoutsQuarterly Earnings Summary & Intraday High Probability Setup Alerts - Newser
Can Alnylam Pharmaceuticals Inc. be the next market leaderIPO Watch & Free Technical Confirmation Trade Alerts - khodrobank.com
Is Alnylam Pharmaceuticals Inc. exposed to political riskJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - khodrobank.com
Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock? - TradingView
Best data tools to analyze Alnylam Pharmaceuticals Inc. stockWeekly Stock Report & Momentum Based Trading Ideas - Newser
RNA Therapeutics Market Size, Top Share | Industry Report, 2034 - Straits Research
Applying big data sentiment scoring on Alnylam Pharmaceuticals IncMarket Trend Report & High Return Trade Guides - Newser
Gene Therapy Market is expected to reach US$ 35.91 Billion by 2033 - openPR.com
Will Alnylam Pharmaceuticals Inc. outperform small cap indexes2025 Buyback Activity & Real-Time Buy Zone Alerts - khodrobank.com
Key resistance and support levels for Alnylam Pharmaceuticals Inc.2025 AllTime Highs & Weekly Top Gainers Trade List - Newser
What does recent volatility data suggest for Alnylam Pharmaceuticals Inc.2025 Trade Ideas & Reliable Intraday Trade Alerts - Newser
Strategies to average down on Alnylam Pharmaceuticals Inc.Market Movers & Safe Entry Point Alerts - Newser
Quantitative breakdown of Alnylam Pharmaceuticals Inc. recent move2025 Technical Overview & Safe Entry Trade Signal Reports - Newser
What moving averages say about Alnylam Pharmaceuticals Inc.2025 Macro Impact & Free Daily Entry Point Trade Alerts - Newser
Visual analytics tools that track Alnylam Pharmaceuticals Inc. performanceQuarterly Performance Summary & Risk Adjusted Swing Trade Ideas - Newser
Using Python tools to backtest Alnylam Pharmaceuticals Inc. strategiesJuly 2025 Summary & Daily Technical Forecast Reports - Newser
Market reaction to Alnylam Pharmaceuticals Inc.’s recent news2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - Newser
Alnylam at Citi’s Biopharma Conference: Launch Success and Future Plans - Investing.com
Sentiment analysis tools applied to Alnylam Pharmaceuticals Inc.July 2025 Opening Moves & Free Weekly Watchlist of Top Performers - Newser
The Strategic Value of Novartis' $5.2 Billion Argo Biopharma Licensing Deal in the RNAi Cardiovascular Therapeutics Space - AInvest
Technical analysis overview for Alnylam Pharmaceuticals Inc. stockJuly 2025 Outlook & Stepwise Trade Signal Implementation - Newser
How institutional ownership impacts Alnylam Pharmaceuticals Inc. stockJuly 2025 Review & Technical Pattern Recognition Alerts - Newser
Technical signs of recovery in Alnylam Pharmaceuticals Inc.July 2025 Volume & Fast Gaining Stock Reports - Newser
Will breakout in Alnylam Pharmaceuticals Inc. lead to full recovery2025 Earnings Surprises & Safe Entry Point Alerts - Newser
What MACD and RSI say about Alnylam Pharmaceuticals Inc.Earnings Summary Report & Weekly High Potential Alerts - Newser
What to expect from Alnylam Pharmaceuticals Inc. in the next 30 days2025 Trading Recap & Scalable Portfolio Growth Methods - Newser
Using fundamentals and technicals on Alnylam Pharmaceuticals Inc.2025 Geopolitical Influence & Weekly Top Performers Watchlists - Newser
Published on: 2025-09-03 01:05:50 - Newser
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives - Seeking Alpha
Alnylam Pharmaceuticals Inc.’s volatility index tracking explained2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
Chart overlay techniques for tracking Alnylam Pharmaceuticals Inc.Forecast Cut & High Accuracy Trade Alerts - Newser
What’s the analyst consensus on Alnylam Pharmaceuticals Inc.Stock Surge & Weekly Return Optimization Plans - khodrobank.com
Alnylam Shares Edge Up 0.11% on $480M Volume (Rank 222nd) as RNAi Pipeline Drives 70%+ Total Return - AInvest
How sentiment analysis helps forecast Alnylam Pharmaceuticals Inc.Quarterly Performance Summary & Weekly Watchlist for Consistent Profits - Newser
Is Alnylam Pharmaceuticals Inc. forming a breakout pattern2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - khodrobank.com
ALNY Stock: HC Wainwright & Co. Reiterates Buy Rating with $570 PT | ALNY Stock News - GuruFocus
Alnylam stock maintains Overweight rating at Piper Sandler on strong AMVUTTRA data - Investing.com
Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio? - Yahoo Finance
Roche and Alnylam to take zilebesiran into Phase III hypertension trial - The Pharma Letter
Maraganore, Meanwell Launch Corsera, Their Third Act In Cardiovascular Disease - insights.citeline.com
Corsera Health Launches to Extend Healthspan by Predicting and Preventing Cardiovascular Disease - BioSpace
Alnylam reports new analysis from trial of Amvuttra for ATTR-CM - Yahoo Finance
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth amid ATTR-CM market expansion - Investing.com
Startup Corsera Health aims to bring preventive heart medicine to the masses - BioPharma Dive
Does Alnylam Pharmaceuticals Inc. offer margin of safety2025 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - khodrobank.com
Alnylam to advance Roche-partnered heart drug to late-stage trial despite mid-stage setback - MSN
0.61%
5.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):